Etizolam

證據等級: L5

預測適應症: 1 個

Etizolam: From Anxiolytic/Sedative to Insomnia

One-Sentence Summary

Etizolam is a thienodiazepine compound, primarily recognized as an anxiolytic and sedative-hypnotic agent used in select Asian markets (notably Japan and India), acting as a positive allosteric modulator of the GABA-A receptor. The TxGNN model predicts it may be effective for Insomnia, with a prediction score of 99.94%, supported by 0 clinical trials and 4 publications — primarily preclinical and pharmacokinetic in nature.

Quick Overview

Item	Content
Original Indication	Anxiety disorders / sedation (thienodiazepine class; no Taiwan/India regulatory record available)
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.94%
Evidence Level	L4
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on known pharmacological information, Etizolam belongs to the thienodiazepine class and acts as a positive allosteric modulator (PAM) of the GABA-A receptor — a mechanism essentially identical to classical benzodiazepines, but with a thienyl ring replacing the benzene ring in the chemical scaffold. By enhancing GABAergic inhibitory neurotransmission, it produces sedative, hypnotic, anxiolytic, and muscle-relaxant effects. Its half-life of approximately 6 hours (with an active metabolite, α-hydroxy-etizolam, of ~8 hours) is pharmacokinetically suitable for both sleep-onset and sleep-maintenance indications.

The mechanistic link between Etizolam and insomnia is therefore highly plausible. GABA-A receptor modulation is the shared mechanism of virtually all approved benzodiazepine and Z-drug hypnotics (e.g., triazolam, zolpidem, eszopiclone). The very high TxGNN score (0.9994) reflects a strong graph-level association between the GABA pathway nodes and the insomnia disease node in the knowledge graph. Furthermore, a preclinical study (PMID 18789918) directly demonstrated that Etizolam shortened sleep latency and increased non-REM sleep time in rats — consistent with clinical utility for insomnia.

However, mechanistic plausibility does not substitute for clinical evidence. The major safety concern is the well-established class risk of tolerance, dependence, and rebound insomnia upon withdrawal, which is documented even in the limited preclinical literature available for Etizolam specifically. This risk substantially limits the drug’s profile as a long-term insomnia treatment and must be addressed before any clinical development pathway can be recommended.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
18789918	2008	Animal Study (Preclinical)	European Journal of Pharmacology	Etizolam shortened sleep latency and increased non-REM sleep time in rats in a dose-dependent manner; abrupt withdrawal caused significant rebound insomnia (prolonged sleep latency), paralleling triazolam behavior
23330992	2013	Review (PK)	Expert Opinion on Drug Metabolism & Toxicology	Reviewed pharmacokinetics of anxiolytic drugs including thienodiazepines; anxiety disorders represent the most common mental disorders with high comorbidity burden, supporting rational for GABAergic agents
23553148	2013	Case Report	Journal of Anesthesia	Case of neuroleptic malignant syndrome-like symptoms with fever and insomnia emerging on postoperative day 1 following abrupt withdrawal of oral etizolam, highlighting withdrawal-related insomnia risk
29105206	2018	Observational / Cross-sectional	Journal of Paediatrics and Child Health	Identified risk factors for psychological and psychosomatic symptoms (including sleep disturbance) in hospitalised children with malignancies; Etizolam mentioned among medications used for symptom management

India Market Information

Etizolam currently has no registered products in India (or Taiwan) according to the regulatory data in this Evidence Pack. No authorisation table can be generated.

Note: Etizolam is approved and marketed in Japan (as Depas®) and has a complex regulatory status internationally — classified as a controlled/scheduled substance in several jurisdictions including the EU and US. This regulatory landscape is a material consideration for any development strategy in India.

Safety Considerations

Detailed safety data (package insert warnings, contraindications, drug–drug interactions) were not available in this Evidence Pack. Based on class-level knowledge:

Withdrawal / Rebound Insomnia: Directly documented in preclinical data (PMID 18789918); abrupt cessation after sustained use causes significant rebound sleep disturbance — a major concern for an insomnia indication.
Dependence and Tolerance: As a GABAergic PAM, Etizolam carries the standard benzodiazepine class risk of physical dependence, tolerance, and abuse potential.
Controlled Substance Status: Etizolam is classified as a scheduled/controlled substance in multiple jurisdictions; this has direct implications for development pathway, prescribing restrictions, and regulatory strategy in India.

Please refer to the package insert and applicable national controlled substance regulations for comprehensive safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence is currently limited to preclinical animal studies and pharmacokinetic reviews with no registered clinical trials for the insomnia indication; the L4 evidence level, combined with the drug’s controlled substance status and known rebound insomnia risk, does not support advancing to feasibility analysis without first resolving the data gaps and regulatory constraints.

To proceed, the following is needed:

Regulatory classification clarification: Determine Etizolam’s current legal/scheduling status in India — whether it is permissible to develop, import, or study for new indications under the Narcotic Drugs and Psychotropic Substances Act or equivalent regulation.
MOA documentation: Obtain full DrugBank mechanism-of-action data and pharmacodynamic profile to complete the mechanistic link analysis (Data Gap DG002).
Safety data retrieval: Download and parse the Japanese PMDA package insert (Depas®) or equivalent source for full warnings, contraindications, and DDI profile (Data Gap DG001).
Comparative landscape review: Assess whether Etizolam offers any meaningful clinical advantage over already-approved hypnotics (zolpidem, eszopiclone) for insomnia, given the identical GABA-A mechanism and a worse dependence/rebound profile vs. Z-drugs.
Clinical evidence search: Conduct a targeted systematic search in Japanese literature databases (Ichushi-Web / J-STAGE) where Etizolam has been used clinically, to identify any human sleep data not captured by PubMed.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.